Pharmaco - Articles
T-cell therapy is a cutting-edge form of immunotherapy that utilizes the body's own immune system to target and eliminate cancer cells. This innovative approach involves modifying and reprogramming T cells to express specific receptors that enable them to recognize and attack cancer cells.
In recent years, medical research and innovation have witnessed remarkable advancements in the field of immunotherapy, specifically in the realm of T-cell therapy. T-cell therapy is an emerging form of cancer treatment that harnesses the body's own immune system to target and eliminate cancer cells. This groundbreaking approach holds immense promise for patients battling various types of cancer and has the potential to revolutionize the landscape of cancer treatment. At the core of T-cell therapy lies th…
In recent years, medical research and innovation have witnessed remarkable advancements in the field of immunotherapy, specifically in the realm of T-cell therapy. T-cell therapy is an emerging form of cancer treatment that harnesses the body's own immune system to target and eliminate cancer cells. This groundbreaking approach holds immense promise for patients battling various types of cancer and has the potential to revolutionize the landscape of cancer treatment. At the core of T-cell therapy lies th…
The Cambridge cluster began in 1960 with the formation of Cambridge Consultants as a way of linking the technical expertise of the university with the needs of industry. Today, it comprises around 5,000 knowledge intensive firms, employing 61,000 people and generating combined annual revenues of more than £15.5billion. As one of Europe’s largest technology clusters, it is a significant success but there is still some frustration that it is not meeting its true potential.
The Cambridge cluster began in 1960 with the formation of Cambridge Consultants as a way of linking the technical expertise of the university with the needs of industry. Today, it comprises around 5,000 knowledge intensive firms, employing 61,000 people and generating combined annual revenues of more than £15.5billion. As o…
The Cambridge cluster began in 1960 with the formation of Cambridge Consultants as a way of linking the technical expertise of the university with the needs of industry. Today, it comprises around 5,000 knowledge intensive firms, employing 61,000 people and generating combined annual revenues of more than £15.5billion. As o…
In this article, Saama's Chief Technology Officer, Lisa Moneymaker, writes about how AI technology could be implemented to help data managers keep track of all the data coming in from clinical trials, explaining how AI technology will change the pharma industry as more and more companies race to be the first to reach FDA approval.
Over the past decade, data volume has increased threefold, according to the Tufts Center for the Study of Drug Discovery (CSDD). All of this data needs to be collected, secured and analyzed — so newer, better medications can be developed to help patients around the world. Traditional (read: manual) approaches to cleaning and monitoring data simply can’t scale — and the status quo of those processes and systems are coming under greater scrutiny. This has created a…
Over the past decade, data volume has increased threefold, according to the Tufts Center for the Study of Drug Discovery (CSDD). All of this data needs to be collected, secured and analyzed — so newer, better medications can be developed to help patients around the world. Traditional (read: manual) approaches to cleaning and monitoring data simply can’t scale — and the status quo of those processes and systems are coming under greater scrutiny. This has created a…
Here, Bob Tilling, VP Global Sales at Kallik, explains how a comprehensive labelling and artwork management system can prepare manufacturers in highly regulated industries to make fast, efficient label changes when supply chains pressures force ingredients changes, new regulations come into force, or regionalisation is required for certain product lines.
The year 2022 was record year for product recalls in regulated industries with US recalls reaching an all-time high of 1.5 billion impacted units and, 10,545 product recall events across Europe, according to analysis by brand protection and recall risk experts, Sedgwick. When drilling down to the detail many recalls were due to errors on labels and packaging. These recalls were exacerbated by certain external pressures – such as short notic…
The year 2022 was record year for product recalls in regulated industries with US recalls reaching an all-time high of 1.5 billion impacted units and, 10,545 product recall events across Europe, according to analysis by brand protection and recall risk experts, Sedgwick. When drilling down to the detail many recalls were due to errors on labels and packaging. These recalls were exacerbated by certain external pressures – such as short notic…
Colorectal cancer is classified into four stages: stage 0, stage I-cancer in the inner layers of the colon, stage II-cancer spreads through the muscle wall of the colon, stage III-cancer spreads to lymph nodes, and stage IV-cancer spreads to other organs.
Colorectal cancer, also known as colon cancer or rectal cancer, is a type of cancer that affects the colon or rectum. It is the third most common cancer in both men and women worldwide, with an estimated 1.8 million new cases and 900,000 deaths in 2018 alone. In this article, we will discuss the causes, symptoms, diagnosis, treatment, and prevention of colorectal cancer. Colorectal cancer is one of the most commonly found and lethal cancers developed in individuals with the combined influence of genetic and environmental factors. Accordin…
Colorectal cancer, also known as colon cancer or rectal cancer, is a type of cancer that affects the colon or rectum. It is the third most common cancer in both men and women worldwide, with an estimated 1.8 million new cases and 900,000 deaths in 2018 alone. In this article, we will discuss the causes, symptoms, diagnosis, treatment, and prevention of colorectal cancer. Colorectal cancer is one of the most commonly found and lethal cancers developed in individuals with the combined influence of genetic and environmental factors. Accordin…
The global lab automation market is projected to reach USD 7.1 billion by 2028 from USD 5.1 billion in 2022, growing at a CAGR of 5.8%
Overview of Growth Trends, Applications, Benefits, and Future Outlook: The Lab Automation market is a rapidly growing industry that is focused on the automation of laboratory processes and systems. This market is driven by the need to reduce operational costs and increase efficiency, as well as the need to improve accuracy and consistency in laboratory results. Lab automation solutions include automated laboratory equipment, robotic systems, laboratory information management systems, laboratory software, and other related services. These solutions are used in a variety of industries, including pharmaceuticals, medical diagnostics, biotechnology, and research…
Overview of Growth Trends, Applications, Benefits, and Future Outlook: The Lab Automation market is a rapidly growing industry that is focused on the automation of laboratory processes and systems. This market is driven by the need to reduce operational costs and increase efficiency, as well as the need to improve accuracy and consistency in laboratory results. Lab automation solutions include automated laboratory equipment, robotic systems, laboratory information management systems, laboratory software, and other related services. These solutions are used in a variety of industries, including pharmaceuticals, medical diagnostics, biotechnology, and research…
Wet signatures, where a mark is made with a pen on a piece of paper, have long been the gold standard for providing an irrefutable mark of intent, identity and for agreement. For centuries, ink has held sway over legal and other important documents, with a scribble on a piece of paper proving any number of things. And that’s part of the problem.
Wet signatures, where a mark is made with a pen on a piece of paper, have long been the gold standard for providing an irrefutable mark of intent, identity and for agreement. For centuries, ink has held sway over legal and other important documents, with a scribble on a piece of paper proving any number of things. And that’s part of the problem. In the modern era, despite the much-publicised shift to digital, the pharmaceutical industry still places…
Wet signatures, where a mark is made with a pen on a piece of paper, have long been the gold standard for providing an irrefutable mark of intent, identity and for agreement. For centuries, ink has held sway over legal and other important documents, with a scribble on a piece of paper proving any number of things. And that’s part of the problem. In the modern era, despite the much-publicised shift to digital, the pharmaceutical industry still places…
From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry. Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine, and soaring input costs weighing on manufacturers.
From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry.Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine,…
From over-the-counter flu tablets to crucial antibiotics and antidepressants, medicines are running scarce in UK pharmacies this year, causing concerns among patients, the government, and the wider pharma industry.Drug shortages have accelerated over the past year due to a clutch of problems including the after-effects of the pandemic on supply chains, the war in Ukraine,…
01-Mar-2023
There is an ongoing trend in the pharmaceutical industry to outsource activities to external vendors. When such outsourcing affects GMDP-activities, and is therefore related to EU Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP), defined regulatory requirements must be respected in the process of outsourcing.
There is an ongoing trend in the pharmaceutical industry to outsource activities to external vendors. When such outsourcing affects GMDP-activities, and is therefore related to EU Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP), defined regulatory requirements must be respected in the process of outsourcing. One of the main misunderstandings that I observe in my role as an auditor and GxP-consultant is that outsourcing of activities does not m…
There is an ongoing trend in the pharmaceutical industry to outsource activities to external vendors. When such outsourcing affects GMDP-activities, and is therefore related to EU Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP), defined regulatory requirements must be respected in the process of outsourcing. One of the main misunderstandings that I observe in my role as an auditor and GxP-consultant is that outsourcing of activities does not m…
As the Life Sciences industry embraces a future that is data rather than document driven, companies have some practical questions to answer, such as who will make this happen? Thought leaders from BioNTech, Bayer, Iperion - a Deloitte business, and Beczek.COM recently came together for a Big Debate on the topic over video link. Generis COO Max Kelleher chaired the proceedings.
On the panel were: Dr. Melanie Ruppel, Senior Director Global Regulatory Affairs Regulatory Operations, BioNTech Vada A. Perkins, Executive Director, Regulatory Policy & Intelligence and Head of Regulatory Intelligence, Bayer Pharmaceuticals Frits Stulp, Managing Director, Iperion - a Deloitte business Preeya Beczek, Director & Independent Regulatory Affairs Expert, Beczek.COM Frits Stulp of Iperion – a Delo…
On the panel were: Dr. Melanie Ruppel, Senior Director Global Regulatory Affairs Regulatory Operations, BioNTech Vada A. Perkins, Executive Director, Regulatory Policy & Intelligence and Head of Regulatory Intelligence, Bayer Pharmaceuticals Frits Stulp, Managing Director, Iperion - a Deloitte business Preeya Beczek, Director & Independent Regulatory Affairs Expert, Beczek.COM Frits Stulp of Iperion – a Delo…
After practical supply chain issues in 2022, added to the impact of continued medicinal/device innovation, 2023 will bring new regulatory changes linked to process digitalisation and automation. REPHINE’s Dr. Eduard Cayón discusses the implications for Quality control.
Never before has the Life Sciences industry needed a robust manufacturing and supply chain Quality backbone as it does now. Advanced markets such as Europe and North America are already well used to strict controls and audits, but standards are being raised right around the world now - from South America to the Middle East and Asia. The pandemic, the war in Ukraine, and innovation-based disruption at the core of the industry have contributed to a renewed focus on supply chain security and quality. The upshot is that manufactu…
Never before has the Life Sciences industry needed a robust manufacturing and supply chain Quality backbone as it does now. Advanced markets such as Europe and North America are already well used to strict controls and audits, but standards are being raised right around the world now - from South America to the Middle East and Asia. The pandemic, the war in Ukraine, and innovation-based disruption at the core of the industry have contributed to a renewed focus on supply chain security and quality. The upshot is that manufactu…
21-Feb-2023
As the Life science sector evolves, being on top of new trends and regulations is essential for success. By navigating the complexities of risk-based systems, leveraging cutting-edge technology such as artificial intelligence (AI), and prioritizing their supply chains, companies in Ireland can remain at the forefront of the industry in 2023." That's according to Jane Lyons, Country Manager, PharmaLex Ireland, the leading provider of specialised services to the Life Sciences industry worldwide.
As the Life science sector evolves, being on top of new trends and regulations is essential for success. By navigating the complexities of risk-based systems, leveraging cutting-edgetechnology such as artificial intelligence (AI), and prioritizing their supply chains, companies in Ireland can remain a…
As the Life science sector evolves, being on top of new trends and regulations is essential for success. By navigating the complexities of risk-based systems, leveraging cutting-edgetechnology such as artificial intelligence (AI), and prioritizing their supply chains, companies in Ireland can remain a…
In this article Jon Geater, chief technology officer at RKVST, introduces a new acronym, SCITT, provides some explanation and discusses why it is important for the pharmaceutical industry.
What is SCITT? While it may be yet another term you might not have heard of, it’s sure to become more familiar to pharmaceutical industry players as we strive to ensure traceability, accountability, and auditability across the supply chain. The term SCITT stands for ‘Supply Chain Integrity, Transparency, and Trust’. While there’s ongoing discussion over its scope and definition, at its core, it’s pretty simple: risk vests in the operator of equipment but originates at every point in the supply chain. If pharmaceutical companies and other players in the pharma supply chain are to take control of, and res…
What is SCITT? While it may be yet another term you might not have heard of, it’s sure to become more familiar to pharmaceutical industry players as we strive to ensure traceability, accountability, and auditability across the supply chain. The term SCITT stands for ‘Supply Chain Integrity, Transparency, and Trust’. While there’s ongoing discussion over its scope and definition, at its core, it’s pretty simple: risk vests in the operator of equipment but originates at every point in the supply chain. If pharmaceutical companies and other players in the pharma supply chain are to take control of, and res…
24-Feb-2023
Working in the life science industry can be extremely rewarding, with a unique opportunity to save lives and improve the quality of life for patients across the globe. Whether you see yourself working in a laboratory researching molecules for use in drug development, or in an office processing contracts and other legal documents to kickstart a clinical trial, the work you do in the industry has a real, meaningful impact on people’s lives worldwide.
Working in the life science industry can be extremely rewarding, with a unique opportunity to save lives and improve the quality of life for patients across the globe. Whether you see yourself working in a laboratory researching molecules for use in drug development, or in an office processing contracts and other legal documents to kickstart a cl…
Working in the life science industry can be extremely rewarding, with a unique opportunity to save lives and improve the quality of life for patients across the globe. Whether you see yourself working in a laboratory researching molecules for use in drug development, or in an office processing contracts and other legal documents to kickstart a cl…
21-Dec-2022
Below is an overview of the types of content we will be looking to publish on PharmiWeb.com in 2023. Please note that this schedule may change at any time, and that all content will be reviewed by us prior to publication. If you have any questions about our calendar and editorial guidelines, please get in touch with us at editor@pharmiweb.com – we’d be happy to help.
Below is an overview of the types of content we will be looking to publish on PharmiWeb.com in 2023. Please note that this schedule may change at any time and that we will review all content prior to publication. If you have any questions about our calendar and editorial guidelines, please contact us at editor@pharmiweb.com – we’d be happy to help. View our full editorial guidelines here. Month Industry Topic(s) Recruitment…
Below is an overview of the types of content we will be looking to publish on PharmiWeb.com in 2023. Please note that this schedule may change at any time and that we will review all content prior to publication. If you have any questions about our calendar and editorial guidelines, please contact us at editor@pharmiweb.com – we’d be happy to help. View our full editorial guidelines here. Month Industry Topic(s) Recruitment…
Today, the pharmaceutical industry emits more greenhouse gases globally than the automotive sector, equating to about 48.5 tonnes of carbon dioxide for every $1m generated. Every single stage of the pharmaceutical supply chain has a carbon footprint, from the moment raw materials are sourced, to the energy-intensive processes in building molecules, and all the way to shipping packaged products to hospitals and pharmacy shelves.
Today, the pharmaceutical industry emits more greenhouse gases globally than the automotive sector, equating to about 48.5 tonnes of carbon dioxide for every $1m generated. Every single stage of the pharmaceutical supply chain has a carbon footprint, from the moment raw materials are sourced, to the energy-intensive processes in building molecules, and all the way to…
Today, the pharmaceutical industry emits more greenhouse gases globally than the automotive sector, equating to about 48.5 tonnes of carbon dioxide for every $1m generated. Every single stage of the pharmaceutical supply chain has a carbon footprint, from the moment raw materials are sourced, to the energy-intensive processes in building molecules, and all the way to…
EU GMP Annex 1 requirements for Manufacture of Sterile Medicinal Products were revised in August 2022, starting the clock for compliance by August 2023. Anna Cluet of Rephine offers some practical steps to address the requirements relating to Contamination Control Strategy (CCS), reducing the possibility of human contamination, and ensuring quality throughput the product lifecycle.
In August 2022, revised EU GMP Annex 1 requirements related to the Manufacture of Sterile Medicinal Products were issued, starting the clock for compliance. All but one of the new provisions must be fulfilled by August 2023. The updated requirements, designed to protect and increase confidence in the sterility of these products, are significant and wide-ranging, spanning the Quality system and the manufacturing p…
In August 2022, revised EU GMP Annex 1 requirements related to the Manufacture of Sterile Medicinal Products were issued, starting the clock for compliance. All but one of the new provisions must be fulfilled by August 2023. The updated requirements, designed to protect and increase confidence in the sterility of these products, are significant and wide-ranging, spanning the Quality system and the manufacturing p…
Since 2020, market disruption created by COVID-19 has primed every aspect of the pharma industry for change: something that they have been reluctant to do in the decades previous. Today, with more crises potentially awaiting around the corner, there is an openness across the pharmaceutical world to embrace new technologies with a sense of urgency. Here are five important ways technology and automation can support pharma companies with mitigating increased complexity and seizing opportunities.
Since 2020, market disruption created by COVID-19 has primed every aspect of the pharma industry for change: something that they have been reluctant to do in the decades previous. . Today, with more crises potentially awaiting around the corner, there is an openness across the pharmaceutical world to e…
Since 2020, market disruption created by COVID-19 has primed every aspect of the pharma industry for change: something that they have been reluctant to do in the decades previous. . Today, with more crises potentially awaiting around the corner, there is an openness across the pharmaceutical world to e…
As the life science industry continues to embrace more flexible ways of working, you may find yourself managing a team of hybrid or remote workers. As hybrid and remote working come with their own set of both challenges and opportunities, these ways of working also require a very different managerial approach.
As the life science industry continues to embrace more flexible ways of working, you may find yourself managing a team of hybrid or remote workers. As hybrid and remote working come with their own set of both challenges and opportunities, these ways of working also require a very different managerial approach. We’ve put together this list of 14 best practices when it comes to managing your remote pharma employees, from retraining to recognising signs of burnout… Provide Training on Ke…
As the life science industry continues to embrace more flexible ways of working, you may find yourself managing a team of hybrid or remote workers. As hybrid and remote working come with their own set of both challenges and opportunities, these ways of working also require a very different managerial approach. We’ve put together this list of 14 best practices when it comes to managing your remote pharma employees, from retraining to recognising signs of burnout… Provide Training on Ke…
Bachem, the Swiss pharmaceutical company, invested in a capacity expansion for large-scale production of oligonucleotide active pharmaceutical ingredients (APIs).
Each step within the company’s oligonucleotide manufacturing process uses unique, innovative equipment to deliver the highest-quality products and to increase sustainability. Tailor-made oligonucleotide synthesisers To ensure only the highest-quality oligonucleotide is supplied to customers, Bachem designed a large-scale oligonucleotide synthesiser. This synthesiser optimises the process of oligonucleotide synthesis and has been qualified for GMP batches from a 0.2 mol to 2 mol scale. One of the engineering solutions used for the innovative synthesiser is in-line mixing of dichloroacetic acid (DCA) and toluene. This solution is u…
Each step within the company’s oligonucleotide manufacturing process uses unique, innovative equipment to deliver the highest-quality products and to increase sustainability. Tailor-made oligonucleotide synthesisers To ensure only the highest-quality oligonucleotide is supplied to customers, Bachem designed a large-scale oligonucleotide synthesiser. This synthesiser optimises the process of oligonucleotide synthesis and has been qualified for GMP batches from a 0.2 mol to 2 mol scale. One of the engineering solutions used for the innovative synthesiser is in-line mixing of dichloroacetic acid (DCA) and toluene. This solution is u…
